CardioRenal Systems discovered first-of-its-kind RenalGuard Therapy® device to prevent Acute Kidney Injury (AKI) in patients at high risk for Cardiac Surgery Associated AKI (CSA-AKI).
RenalGuard Therapy® helps to reduce the prevalence of CSA-AKI, the length and cost of hospitalisation, and improves patients' quality of life.
RenalGuard® is designed to protect the kidneys with personalised, active hydration. This is done by maximising urine output, while balancing hydration through real-time urine output monitoring and IV infusion with the help of a smart re-hydration system.
Globally, Acute Kidney Injury affects millions of hospitalised patients. It is reported that, every year in United States, Europe, and the Middle East, over 780,000 heart surgeries are performed, and AKI is present in 30% of cases, and is the most common major surgical complication. Up to 80 percent of patients have risk factors that make them high. AKI complicates patient recovery, significantly prolongs ICU stay, and is one of the strongest predictors of in-hospital and long-term mortality after surgery.
FDA has granted Breakthrough Device Designation for RenalGuard Therapy® device for the prevention of Acute Kidney Injury (AKI) in patients at risk for Cardiac Surgery Associated AKI (CSA-AKI).
